Lilly’s EBGLYSS gains FDA approval for patients aged 12 and older

Eli Lilly and Company has announced the FDA approval of EBGLYSS for treating atopic dermatitis in adults and children over 12.

Sep 16, 2024 - 04:00

Lilly’s EBGLYSS gains FDA approval for patients aged 12 and older

Eli Lilly and Company has announced the FDA approval of EBGLYSS for treating atopic dermatitis in adults and children over 12.

Read the original article

Tags:

Previous Article

EASD 2024: Innovent shows off mazdutide’s efficacy in diabetes and obesity

ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Johnson & Johnson reports 6.3% rise in Q2 2023 sales

Johnson & Johnson reports 6.3% rise in Q2 2023 sales

Jul 21, 2023

STAT+: Microsoft strikes partnership with Duke Health to advance AI in medicine

STAT+: Microsoft strikes partnership with Duke Health t...

Aug 1, 2023

She got off dialysis. Her doctor thinks others with acute kidney injury can too

She got off dialysis. Her doctor thinks others with acu...

Sep 28, 2023